The interaction between platelet glycoprotein Ib and von Willebrand factor (vWF) plays a crucial role in platelet-mediated thrombus formation under high-shear-stress conditions. The aim of this study was to investigate the antiplatelet profile of a humanized anti-vWF monoclonal antibody, AJW200. In vitro studies were performed with a modified cone-and-plate viscometer and human platelets. AJW20...

Platelet activation and aggregation are considered to be central to arterial thrombus formation. Antiplatelet therapy is therefore important for both the treatment and prevention of cardiovascular disease. Aspirin, the most widely used antiplatelet agent, inhibits platelet cyclo-oxygenase and the conversion of arachidonic acid to the potent platelet agonist thromboxane A(2) but does not prevent...

Rupture of the vulnerable atherosclerotic plaque in the coronary artery wall leading to activation and aggregation of platelets to form an artery occluding thrombus is the most frequent cause of acute myocardial infarction (AMI) [1–3]. Cessation of blood flow in the infarct-related artery (IRA) launches the processes of irreversible myocardial injury, which can be stopped by prompt opening of t...

Platelet activation and aggregation are considered to be central to arterial thrombus formation. Antiplatelet therapy is therefore important for both the treatment and prevention of cardiovascular disease. Aspirin, the most widely used antiplatelet agent, inhibits platelet cyclo-oxygenase and the conversion of arachidonic acid to the potent platelet agonist thromboxane A2 but does not prevent p...

The effects of various statins on platelet aggregation in blood samples from normal and diabetic rabbits were measured. All of the statins used in our study inhibited platelet aggregation by about 20% at 1 microM. Our results show that diabetes increased the rate of platelet aggregation from 48 +/- 5% to 72 +/- 8%, however, statins inhibited the rate of platelet aggregation by about 60% (p < 0....

The antithrombogenic endothelial cell defense (ATECD) describes the properties that enable the endothelium to prevent circulating blood platelets from adhering to, or aggregating on, the vascular wall. ATECD was investigated in an experimental model in which bovine passage 0 cultured endothelial cells (EC) were incubated with aggregating platelets and autologous plasma in a computer-operated ag...

Cardiovascular disease (CVD) and its complications are the most common causes of mortality morbidity worldwide. It is shown that patients with myocardial infarctions (MIs) have high platelets activation aggregation rates which lead to atherothrombosis after rupture an unstable atherosclerotic plaque. Therefore, antiplatelet therapy has become important part secondary prevention cardiovascular d...

Antiplatelet agents such as aspirin, clopidogrel, and dipyridamole are effective in secondary stroke prevention with single agents reducing risk by 15% to 20%1–3; the addition of a second agent (eg, combining aspirin and dipyridamole) doubles this benefit.3 As with other vascular prevention strategies, eg lowering blood pressure and cholesterol, antiplatelet agents reduce, not abolish, risk. De...

BACKGROUND The bleeding impact of dual antiplatelet therapy (DAPT), aspirin and clopidogrel, maintained until coronary artery bypass graft surgery (CABG), is still a matter of debate. The lack of preoperative antiplatelet activity measurement and heterogeneity of antifibrinolytic protocols in prior studies make the conclusions questionable. The aim of this prospective study was to determine, af...

SEE PAGES 2309 AND 2318 D rugs that inhibit platelet activation and aggregation reduce vascular events, notably myocardial infarction (MI) and ischemic stroke, and are generally associated with low rates of bleeding (1). Available agents inhibit platelets via distinct mechanisms (Table 1) (2), and combining antiplatelet drugs with different mechanisms of action should enhance net antithrombotic...